Aeglea BioTherapeutics Priced, Nasdaq: AGLE

Developing enzymes for rare genetic metabolic diseases and tumors.

Industry: Health Care

Latest Trade: $4.35 0.00 (0.0%)

First Day Return: -2.3%

Return from IPO: -56.5%

Industry: Health Care

We are a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism that we believe will transform the lives of patients with inborn errors of metabolism and cancer. Our engineered human enzymes are designed to degrade specific amino acids in the blood. In inborn errors of metabolism, or IEM, a subset of rare genetic metabolic diseases, we are seeking to reduce toxic levels of amino acids in patients. In oncology, we are seeking to reduce amino acid blood levels below the normal range, where we believe we will be able to exploit the dependence of certain cancers on specific amino acids.
more less
IPO News for Aeglea BioTherapeutics
more
IPO Data
IPO File Date 06/16/2015
Offer Price $10.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.0
Deal Size ($mm) $50
IPO Data
IPO Date 04/06/2016
Offer Price $10.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.0
Deal Size ($mm) $50
Underwriters
more
Company Data
Headquarters Austin, TX
Founded 2013
Employees 23
Website www.aegleabio.com